Back to top
more

ALX Oncology Holdings (ALXO)

(Delayed Data from NSDQ)

$0.52 USD

0.52
415,913

-0.05 (-8.70%)

Updated Aug 1, 2025 04:00 PM ET

After-Market: $0.52 0.00 (0.37%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth C Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (143 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

ALX Oncology Holdings (ALXO) Could Find a Support Soon, Here's Why You Should Buy the Stock Now

by Zacks Equity Research

ALX Oncology Holdings (ALXO) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

Zacks Equity Research

Is ALX Oncology Holdings (ALXO) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how ALX Oncology Holdings Inc. (ALXO) and Ginkgo Bioworks Holdings, Inc. (DNA) have performed compared to their sector so far this year.

Zacks Equity Research

ALX Oncology Holdings (ALXO) Loses -27.11% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

by Zacks Equity Research

ALX Oncology Holdings (ALXO) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Zacks Equity Research

uniQure (QURE) Soars on New Huntington's Disease Study Data

by Zacks Equity Research

uniQure (QURE) surges 77% on updated positive interim data from 29 treated patients in the ongoing phase I/II studies of investigational gene therapy, AMT-130, for Huntington's disease.

Zacks Equity Research

IDEAYA (IDYA) Up on Upbeat Phase II Bladder & Lung Cancer Data

by Zacks Equity Research

IDEAYA (IDYA) gains 15% on positive clinical data from its phase II study evaluating the 30 mg monotherapy expansion dose of IDE397 to treat MTAP-deletion urothelial and NSCLC patients.

Zacks Equity Research

Adicet (ACET) Up as Kidney Cancer Drug Gets FDA's Fast Track Tag

by Zacks Equity Research

Adicet (ACET) gains as the FDA grants the Fast Track designation to ADI-270 for the potential treatment of a form of kidney cancer. A phase I study for this indication is set to begin in 2024.

Zacks Equity Research

Dianthus (DNTH) Gains 18% in the Past Month: Here's Why

by Zacks Equity Research

Dianthus (DNTH) shares have rallied 18% in the past month on FDA clearance to initiate a phase II study on its lead candidate, DNTH103, to treat an autoimmune indication. Top-line data is expected in 2026.

Zacks Equity Research

Roche (RHHBY) Receives FDA Nod for Vabysmo Prefilled Syringe

by Zacks Equity Research

The FDA approves Roche's (RHHBY) Vabysmo prefilled syringe for treating three retinal conditions that can cause blindness.

Zacks Equity Research

Apellis' (APLS) Syfovre Boost Sales, Regulatory Setbacks a Woe

by Zacks Equity Research

Apellis' (APLS) revenues rise on the back of the robust uptake of Syfovre for the GA indication. However, the recent regulatory setback in the EU for pegcetacoplan to treat GA is a woe.

Zacks Equity Research

Roche's (RHHBY) Combo Therapy Misses Lung Cancer Study Goals

by Zacks Equity Research

Roche (RHHBY) announces that its mid to late-stage lung cancer study evaluating the tiragolumab combination therapy compared with Keytruda fails to meet primary endpoints.

Zacks Equity Research

Cartesian (RNAC) MG Study Meets Goals, Stock Down on Other Updates

by Zacks Equity Research

Cartesian (RNAC) announced that the phase IIb study in MG patients has achieved its primary endpoints. However, the stock nosedives following an equity financing announcement.

Zacks Equity Research

Annovis (ANVS) Up as Its Lead Candidate Meets Goals in PD Study

by Zacks Equity Research

Annovis (ANVS) surges 76% on Jul 2 after meeting the primary and secondary goals with statistical significance in the late-stage PD study of its lead candidate, buntanetap.

Zacks Equity Research

Regeneron (REGN), SNY Win EC Approval for Dupixent for COPD

by Zacks Equity Research

Regeneron (REGN) and partner Sanofi get approval for their blockbuster drug Dupixent for the chronic obstructive pulmonary disease indication in the EU.

Zacks Equity Research

Longboard (LBPH) Up 14% as Epilepsy Drug Gets Breakthrough Tag

by Zacks Equity Research

Longboard (LBPH) gains 14% as the FDA grants the Breakthrough Therapy designation to its investigational epilepsy treatment candidate, bexicaserin, for patients aged two years or older.

Zacks Equity Research

Mesoblast (MESO) Soars 208% YTD on Positive Regulatory Updates

by Zacks Equity Research

Mesoblast (MESO) skyrockets 208.2% year to date on encouraging progress with its pipeline candidates.

Zacks Equity Research

Roche (RHHBY) Gets Positive CHMP Recommendation for Its Drugs

by Zacks Equity Research

Roche (RHHBY) gets CHMP recommendation for a label expansion of ophthalmology drug Vabysmo (faricimab) and PiaSky (crovalimab) for the treatment of paroxysmal nocturnal haemoglobinuria.

Zacks Equity Research

Apellis (APLS) Falls on Second Negative CHMP Opinion for GA Drug

by Zacks Equity Research

Apellis (APLS) declines as CHMP issues a second negative opinion for the approval of intravitreal pegcetacoplan to treat GA in the EU. The company plans to seek re-examination of the same.

Zacks Equity Research

PTC Therapeutics (PTCT) Down on Negative CHMP Opinion on DMD Drug

by Zacks Equity Research

PTC Therapeutics (PTCT) falls as the EC's advisory committee adopts a negative opinion regarding the renewal of the conditional marketing approval of Translarna to treat nmDMD in the EU.

Zacks Equity Research

Cogent (COGT) Up on SUMMIT Study Update Post Positive FDA Meeting

by Zacks Equity Research

Cogent (COGT) announces a positive FDA meeting and alignment on MS2D2, a novel patient-reported outcome measure for the SUMMIT study. The company's shares rise on the news.

Zacks Equity Research

Denali (DNLI) Outperforms Industry in 3 Months: Here's Why

by Zacks Equity Research

Denali (DNLI) gains 11.9% in three months on positive updates on its candidates.

Zacks Equity Research

Merck's (MRK) New Pneumococcal Jab Capvaxive Gets CDC Panel Vote

by Zacks Equity Research

Merck's (MRK) vaccine, Capvaxive, gets unanimous recommendation by a CDC committee for adults aged 65 years and older for pneumococcal vaccination and those with certain other underlying conditions.

Zacks Equity Research

Dr. Reddy's (RDY) to Acquire Haleon's Nicotine Addiction Drug

by Zacks Equity Research

Dr. Reddy's (RDY) is set to acquire Haleon's leading global NRT brand, Nicotinell, and its related portfolio across all formats of the drug for GBP 500 million to boost its OTC presence worldwide.

Zacks Equity Research

Novo Nordisk's (NVO) Hypertension Drug Study Fails to Meet Goal

by Zacks Equity Research

Novo Nordisk (NVO) declines as a late-stage study of its uncontrolled hypertension and advanced chronic kidney disease candidate, ocedurenone, fails to achieve the primary goal.

Zacks Equity Research

CASI Pharmaceuticals (CASI) Up on Buyout Offer for China Business

by Zacks Equity Research

CASI Pharmaceuticals (CASI) gets a proposal letter from its chairman for acquiring its business operations in China. Its shares rise on the news.

Zacks Equity Research

Bayer's (BAYRY) AskBio Advances Parkinson Disease Study

by Zacks Equity Research

Bayer's (BAYRY) wholly owned and independently operating subsidiary AskBio started recruitment in the phase II study for Parkinson's disease.